CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo

Z. A. Cao
2006 Molecular Cancer Therapeutics  
CRA-026440 is a novel, broad-spectrum, hydroxamic acid -based inhibitor of histone deacetylase (HDAC) that shows antitumor and antiangiogenic activities in vitro and in vivo preclinically. CRA-026440 inhibited pure recombinant isozymes HDAC1, HDAC2, HDAC3/SMRT, HDAC6, HDAC8, and HDAC10 in the nanomolar range.
doi:10.1158/1535-7163.mct-06-0042 pmid:16891455 fatcat:bkqsz5vzp5gdzbgb2e4prdbtue